Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|December 1, 2007
- Pharmaceutical Executive-12-01-2007
- Volume 0
- Issue 0
The List
Author(s)Walter Armstrong, Senior Editor
It's that time of year again, when Santas everywhere take stock of nice and naughty in order to fill stockings-and magazines make up their lists of hits and has-beens.
Advertisement
It's that time of year again, when Santas everywhere take stock of nice and naughty in order to fill stockings—and magazines make up their lists of hits and has-beens. Here, at Pharm Exec, as we considered such weighty matters as which company's hot, which CEO's in the hot seat, and which ones are yesterday's news, we had to acknowledge the silliness of it all to an industry that makes lifesaving drugs and billion-dollar profits. Honest! Now let's dish.
Articles in this issue
almost 19 years ago
Financing the Future of Pharmaalmost 19 years ago
Special Delivery: A Guide to the New Technologiesalmost 19 years ago
Inviting Innovationalmost 19 years ago
Reach for the Radioalmost 19 years ago
The Pharm Exec Pipeline Report 2007almost 19 years ago
Rethinking Vaccines: Q&A with Jane Quinn, GlaxoSmithKlinealmost 19 years ago
Getting Personalalmost 19 years ago
What Moratorium?almost 19 years ago
R&D Innovation: Climbing OutAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
Rebuilding Clinical Data Workflows for the AI Era
5